Diabetes

Investigators also find that patients diagnosed with type 1 diabetes later in life do not have a better prognosis compared to those diagnosed earlier.

Investigators also found that nocturnal hypoglycemia is a strong predictor of daytime hypoglycemia.

Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.

A conversation with Casey Koch, PharmD, MBA, BCACP, clinical pharmacy coordinator at SelectHealth, at Asembia’s AXS25 Summit.

A conversation with Becky Davis, principal at Charles River Associates, at Asembia’s AXS25 Summit.

In the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.

This method supports improved, early detection for diabetes without relying on blood samples or complex procedures.

Further, the authors of the “Standards of Care in Diabetes 2025” highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Investigators find that orforglipron lowered A1c by an average of 1.3% to 1.6% from a baseline of 8% across 3 different dosages.

Furthermore, C-reactive protein has greater prognosis for lung cancer, colorectal cancer, and ovarian cancer.

A conversation with Scott Biggs and Greg Mitchell at the American Associated Pharmacies 2025 Annual Conference.

Pharmacists have positive impacts on health outcomes for diabetes and patients using CGM devices, including reductions in A1c.

Hypertension and obstructive sleep apnea are considered independent risk factors for cardiovascular diseases as well as diabetes.

Further studies are needed to further confirm the association between glucagon-like peptide 1 medication and reductions in dementia risk.

Type 1 diabetes can cause long-term complications, including the development of autoimmune diseases.

Clinical pharmacists counsel patients during the intervention and make informed medication changes based on the data received from continuous glucose monitoring (CGM).

With expertise in the management and treatment of diabetes, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, shared her insights on counseling patients using GLP-1 medications.

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

All 3 types of virtual diabetes self-management interventions lead to better results in hemoglobin A1c over a 6-month period.

The integration of CGM into pharmacy practice represents a significant opportunity for pharmacists to provide enhanced patient care.